FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to new compound of the formula (I) 
or its pharmaceutically acceptable salt or solvate wherein X represents CH or nitrogen atom (N); Z represents CH; R1 represents hydrogen atom; R2 and R3 can be similar or different and represent (C1-C6)-alkoxy-group that is optionally substituted with halogen atom, hydroxyl, (C1-C4)-alkoxycarbonyl, amino-group wherein one or two hydrogen atom are optionally replaced for (C1-C4)-alkyl that is optionally substituted with hydroxyl or (C1-C4)-alkoxy-group, the group R12R13N-C(=O)-O- wherein R12 and R13 can be similar or different and represent hydrogen atom or (C1-C4)-alkyl substituted optionally with (C1-C4)-alkoxy-group or the group R14-(S)m- wherein R14 represents phenyl or saturated or unsaturated 5-7-membered heterocyclic group substituted optionally with (C1-C4)-alkyl; m = 0 or 1; R4 represents hydrogen atom; R5, R6, R7 and R8 can be similar or different and represent hydrogen atom, halogen atom, (C1-C4)-alkyl, (C1-C4)-alkoxy-group or nitro-group under condition that R5, R6, R7 and R don't represent hydrogen atom simultaneously; R9 represents hydrogen atom, (C1-C6)-alkyl or (C1-C4)-alkylcarbonyl wherein alkyl fragment of indicated (C1-C6)-alkyl or (C1-C4)-alkylcarbonyl is optionally substituted with (C1-C4)-alkoxy-group; R10 represents hydrogen atom or (C1-C6)-alkyl; R11 represents (C1-C6)-alkyl, (C2-C6)-alkenyl or (C2-C6)-alkynyl (wherein each (C1-C6)-alkyl, (C2-C6)-alkenyl and (C2-C6)-alkynyl is substituted optionally with halogen atom or (C1-C6)-alkoxy-group), or R15-(CH2)n- wherein n is a whole number from 0 to 3; R15 represents naphthyl or 6-membered saturated or unsaturated carbocyclic or saturated or unsaturated 5-7-membered heterocyclic group that are substituted optionally with halogen atom, (C1-C6)-alkyl or (C1-C6)-alkoxy-group. Also, invention relates to variants of compounds of the formula (I). Compounds elicit antitumor activity and don't effect on cytomorphosis. Also, invention relates to pharmaceutical composition based on above described compounds, to a method for treatment of such diseases as malignant tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and to a method for inhibition of vascular vessels angiogenesis.
EFFECT: valuable medicinal properties of compounds and composition.
22 cl, 4 tbl, 186 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AZOLYL QUINOLINE AND QUINAZOLINE DERIVATIVES, PHARMASEUTICAL COMPOSITION CONTAINING THE SAME, USES THEREOF AND METHOD FOR TREATMENT OF DISEASES | 2002 |
|
RU2283841C2 |
| DERIVATIVES OF QUINAZOLINE | 2002 |
|
RU2302244C2 |
| AROMATIC 6,7-DISUBSTITUTED 3-QUINOLINECARBOXAMIDE DERIVATIVES, METHOD FOR PRODUCTION THEREOF (VARIANTS), PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND USE THEREOF IN DRUG MANUFACTURING | 2002 |
|
RU2281940C2 |
| PHARMACEUTICALLY ACTIVE COMPOUNDS AS Axl INHIBITORS | 2011 |
|
RU2573834C2 |
| QUINAZOLINE DERIVATIVES FOR SLOWING DOWN GROWTH OF CANCER CELLS AND METHOD OF OBTAINING THEM | 2005 |
|
RU2362773C2 |
| 3-HYDROXYQUINAZOLINE-4(3H)-ONE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS AND A METHOD FOR PRODUCTION THEREOF | 2020 |
|
RU2740503C1 |
| NEW BIPHENYL COMPOUND OR ITS SALT | 2016 |
|
RU2726622C2 |
| DERIVATIVES OF INDOLYLPYPERIDINE OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | 1991 |
|
RU2039056C1 |
| COMPOUNDS WITH CONDENSED RINGS | 2019 |
|
RU2783414C2 |
| METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF AN LSD 1INHIBITOR BASED ON THE INSM1 EXPRESSION | 2018 |
|
RU2789449C2 |
